The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Join us for Rare Disease Week: Five Ways to Participate Remotely!
Rare disease day takes place on February 28th each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients.
Tafamidis accepted for FDA Review in 2019
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial,